Results 61 to 70 of about 127,568 (322)

Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy. [PDF]

, 2012
Background The role of a tailored surgical approach for hypertrophic cardiomyopathy (HCM) on regional ventricular remodelling remains unknown. The aims of this study were to evaluate the pattern, extent and functional impact of regional ventricular ...
Cecchi, F, El Guindy, A, El-Hamamsy, I, Lekadir, K, Merrifield, R, Olivotto, I, Rega, L, Yacoub, MH, Yang, G   +8 more
core   +2 more sources

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Cinzia Dello Russo, Iain Frater, Rebecca Kuruvilla, Stefanie Lip, Hannah O'Neill, Kerry Burke, Vicky Chaplin, Alexander S. F. Doney, Salim Elyas, Nicholas Greaves, Sophie Harding, David Hargroves, Judith Hayward, Dyfrig A. Hughes, Tom A. T. Hughes, Sree Kondapally, Patrick Mok, Aaron Peace, Imran Rafi, Simon Ray, Vicky Stinton, Luigi Venetucci, Munir Pirmohamed   +22 more
wiley   +1 more source

Predictive value of estimated plasma volume for postoperative hypotension in percutaneous intramyocardial septal radiofrequency ablation treating for hypertrophic obstructive cardiomyopathy

BMC Cardiovascular Disorders
Background Estimated plasma volume status (ePVS) estimated by the Duarte formula is associated with clinical outcomes in patients with heart failure.
Bo Shan, Jing Li, Zhangwei Shi, Chao Han, Juan Zhang, Jia Zhao, Rui Hu, Liwen Liu, Shengjun Ta   +8 more
doaj   +1 more source

Pathogenesis and potential therapeutic targets of trichorhinophalangeal syndrome; lessons obtained from animal studies

Developmental Dynamics, EarlyView.
Abstract Trichorhinophalangeal syndrome (TRPS) is a rare genetic disease inherited in an autosomal dominant manner. It occurs in 1 in 100,000 people globally and is caused by several types of mutations of the TRPS1 gene. Since the first human patient was reported in 1966, typical and atypical pathologies, disease courses, and treatment case ...
Naoya Saeki, Rinna Kanai, Sayuri Tatsuta, Shinichi Kawaguchi, Masatsune Itoh, Shinsuke Ohba, Makoto Abe   +6 more
wiley   +1 more source

Echocardiography-guided percutaneous intramyocardial alginate hydrogel implants for heart failure: canine models with 6-month outcomes

Frontiers in Cardiovascular Medicine
BackgroundEchocardiography-guided percutaneous intramyocardial alginate-hydrogel implantation (PIMAHI) is a novel treatment approach for heart failure (HF).
Hui Ma, Wenqing Gong, D. Scott Lim, Jing Li, Shengjun Ta, Rui Hu, Xiaojuan Li, Minjuan Zheng, Liwen Liu   +8 more
doaj   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

A review of the molecular mechanisms underlying the development and progression of cardiac remodeling [PDF]

, 2017
Pathological molecular mechanisms involved in myocardial remodeling contribute to alter the existing structure of the heart, leading to cardiac dysfunction.
et al,, Yee, Derek
core   +7 more sources

Identification of a novel titin-cap/telethonin mutation in a Portuguese family with hypertrophic cardiomyopathy

Revista Portuguesa de Cardiologia, 2020
Introduction and objectives: Hypertrophic cardiomyopathy (HCM) is a genetically and phenotypically heterogeneous disease; there is still a large proportion of patients with no identified disease-causing mutation.
Alexandra Toste, Andreas Perrot, Cemil Özcelik, Nuno Cardim   +3 more
doaj   +1 more source

Cardiology: hypertrophic cardiomyopathy [PDF]

Clinical Medicine, 2019
Hypertrophic cardiomyopathy (HCM) is defined by the presence of increased left ventricular (LV) wall thickness (for adults, >15 mm in one or more LV myocardial segments) that is not solely explained by abnormal loading conditions (eg hypertension).
openaire   +2 more sources

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source